Overview

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

Status:
Not yet recruiting

Trial end date:
2023-04-01

Target enrollment:

Participant gender:

Summary

This is a single-arm, open-label, exploratory study to evaluate efficacy and safety of envafolimab combined with endostar and nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer.

Phase:

Phase 2

Details

Lead Sponsor:

The Affiliated Hospital of Xuzhou Medical University

Treatments:

Endostar protein
Endostatins
Gemcitabine
Paclitaxel